157 related articles for article (PubMed ID: 24225054)
1. The efficacy of dapagliflozin combined with hypoglycemic drugs in treating type 2 diabetes: protocol for meta-analysis of randomized controlled trials.
Sun YN; Zhou Y; Chen X; Che WS; Leung SW
Syst Rev; 2013 Nov; 2():103. PubMed ID: 24225054
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.
Sun YN; Zhou Y; Chen X; Che WS; Leung SW
BMJ Open; 2014 Apr; 4(4):e004619. PubMed ID: 24710132
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Dapagliflozin: a review of its use in type 2 diabetes mellitus.
Plosker GL
Drugs; 2012 Dec; 72(17):2289-312. PubMed ID: 23170914
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Feng M; Lv H; Xu X; Wang J; Lyu W; Fu S
Medicine (Baltimore); 2019 Jul; 98(30):e16575. PubMed ID: 31348290
[TBL] [Abstract][Full Text] [Related]
6. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
Albarrán OG; Ampudia-Blasco FJ
Med Clin (Barc); 2013 Sep; 141 Suppl 2():36-43. PubMed ID: 24444523
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
Ann Intern Med; 2012 Mar; 156(6):405-15. PubMed ID: 22431673
[TBL] [Abstract][Full Text] [Related]
8. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S27-38. PubMed ID: 23529568
[TBL] [Abstract][Full Text] [Related]
9. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S16-26. PubMed ID: 23529567
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
[TBL] [Abstract][Full Text] [Related]
11. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
Schumm-Draeger PM; Burgess L; Korányi L; Hruba V; Hamer-Maansson JE; de Bruin TW
Diabetes Obes Metab; 2015 Jan; 17(1):42-51. PubMed ID: 25200570
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis.
Zhuang Y; Song J; Ying M; Li M
Medicine (Baltimore); 2020 Jul; 99(30):e21409. PubMed ID: 32791755
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
[TBL] [Abstract][Full Text] [Related]
14. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin: a review of its use in patients with type 2 diabetes.
Plosker GL
Drugs; 2014 Dec; 74(18):2191-209. PubMed ID: 25389049
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Zhang M; Zhang L; Wu B; Song H; An Z; Li S
Diabetes Metab Res Rev; 2014 Mar; 30(3):204-21. PubMed ID: 24115369
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
Ku EJ; Lee DH; Jeon HJ; Oh TK
Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
[TBL] [Abstract][Full Text] [Related]
19. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
20. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.
Musso G; Gambino R; Cassader M; Pagano G
Ann Med; 2012 Jun; 44(4):375-93. PubMed ID: 21495788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
